Compounders Research Compare

Genprex, Inc.(GNPX)

Biotechnology · Austin, TX

$2.60-0.12 (-4.41%)

Delayed quote: Oct 6, 2026, 10:45 AM EDT

About Genprex, Inc.

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Austin, TX

13 employees

www.genprex.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ryan Confer

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T14:46:59.429Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:46:59.429Z.

Quote observation: 2026-10-06T14:45:04.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,312,831
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 15,154,203
TTM operating income · period ending 2026-06-30: -15,842,711

FMP input reference: 325841a12d79c3b22e4488d0564adef7d4bfa7ba78e5cc1d4c3dcb4b1cd6f762

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

GNPX EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

GNPX Competitors' EV/EBIT Ratio

Genprex, Inc.

Current

Market Cap

$1.31M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Artelo Biosciences, Inc.

Market Cap

$1.38M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NewcelX Ltd.

Market Cap

$1.43M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NEXGEL, Inc.

Market Cap

$1.43M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INVO Fertility, Inc.

Market Cap

$1.45M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Jupiter Neurosciences, Inc.

Market Cap

$1.18M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PMGC Holdings Inc.

Market Cap

$1.45M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Lakewood-Amedex Biotherapeutics, Inc.

Market Cap

$1.46M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IM Cannabis Corp.

Market Cap

$1.17M

EV/EBIT Ratio

N/A

TTM Avg

10.71x

3Y Avg

10.71x

5Y Avg

10.71x

Curis, Inc.

Market Cap

$1.47M

EV/EBIT Ratio

N/A

TTM Avg

439.92x

3Y Avg

439.92x

5Y Avg

439.92x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Genprex, Inc. (GNPX)	$1.31M	N/A	N/A	N/A	N/A
Artelo Biosciences, Inc. (ARTL)vs ›	$1.38M	N/A	N/A	N/A	N/A
NewcelX Ltd. (NCEL)vs ›	$1.43M	N/A	N/A	N/A	N/A
NEXGEL, Inc. (NXGL)vs ›	$1.43M	N/A	N/A	N/A	N/A
INVO Fertility, Inc. (IVF)vs ›	$1.45M	N/A	N/A	N/A	N/A
Jupiter Neurosciences, Inc. (JUNS)vs ›	$1.18M	N/A	N/A	N/A	N/A
PMGC Holdings Inc. (ELAB)vs ›	$1.45M	N/A	N/A	N/A	N/A
Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs ›	$1.46M	N/A	N/A	N/A	N/A
IM Cannabis Corp. (IMCC)vs ›	$1.17M	N/A	10.71x	10.71x	10.71x
Curis, Inc. (CRIS)vs ›	$1.47M	N/A	439.92x	439.92x	439.92x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics